Physician profile
Albert G Driver
NPI 1811973803
$105,605.51
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $6,870 · 2021: $45K · 2022: $1,004 · 2023: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $50,585.29 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $33,408.90 | 2019-2022 | |
| Genzyme Corporation | $12,619.07 | 2019-2021 | |
| Genentech USA, INC. | $4,828.16 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,543.49 | 2019-2023 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $635.22 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $380.18 | 2019-2020 | |
| Insmed, INC. | $370.45 | 2019-2021 | |
| Mylan Specialty L.P. | $236.60 | 2019-2021 | |
| Grifols USA, LLC | $117.98 | 2019-2021 | |
| Circassia INC. | $93.38 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $89.29 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.97 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $68.54 | 2019 | |
| Philips North America LLC | $67.01 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $66.07 | 2021 | |
| Shire North American Group INC | $64.21 | 2019 | |
| Harmony Biosciences LLC | $54.13 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $44.80 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $42.97 | 2019-2020 | |
| Eisai INC. | $34.43 | 2021 | |
| Mallinckrodt Hospital Products INC. | $34.14 | 2020 | |
| Vapotherm INC | $32.56 | 2021-2022 | |
| Advanced Respiratory, INC | $27.75 | 2020 | |
| Paratek Pharmaceuticals, INC. | $21.57 | 2021 | |
| Gilead Sciences, INC. | $21.00 | 2021 | |
| United Therapeutics Corporation | $20.76 | 2019 | |
| Merck Sharp & Dohme LLC | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Driver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.